Impact of interleukin-10 polymorphisms (-1082 and -3575) on the survival of patients with lymphoid neoplasms

Haematologica

Volumn 92, Issue 11, 2007, Pages 1475-1481

  Domingo Domènech, Eva ^a   Benavente, Yolanda ^a   González Barca, Eva ^a   Montalban, Carlos ^b   Gumà, Josep ^c   Bosch, Ramón ^d   Wang, Sophia S ^e   Lan, Qing ^e   Whitby, Denise ^f   De Sevilla, Alberto Fernández ^a   Rothman, Nathaniel ^e   De Sanjosé, Sílvia ^a  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^d HOSPITAL VERGE DE LA CINTA   (Spain)

^e NATIONAL CANCER INSTITUTE   (United States)

^f Institut Català d'Oncologia ^*

Author keywords

IL 10 polymorphisms; Lymphoid neoplasms; Survival

Indexed keywords

INTERLEUKIN 10;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CHILD; COMPARATIVE STUDY; COMPUTER PROGRAM; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; GENOTYPE; HAPLOTYPE; HUMAN; IMMUNE RESPONSE GENE; INFANT; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEWBORN; NONHODGKIN LYMPHOMA; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL; SURVIVAL TIME;

CASE-CONTROL STUDIES; GENOTYPE; HAPLOTYPES; HUMANS; INTERLEUKIN-10; LYMPHOMA; MULTIVARIATE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; SPAIN; SURVIVAL RATE;

EID: 36349003600     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11350     Document Type: Article

References (24)

1. Moreau EJ, Matutes E, A'Hern RP, Morilla AM, Morilla RM, Owusu-Ankomah KA, et al. Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). Am J Clin Pathol 1997;108:378-82.
2. Lech-Maranda E, Baseggio L, Bienvenu J, Charlot C, Berger F, Rigal D, et al. Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. Blood 2004; 103:3529-34.
3. Sarris AH, Kliche KO, Pethambaram P, Preti A, Tucker S, Jackow C et al. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Ann. Oncol 1999;10:433-40.
4. Stewart JP, Behm FG, Arrand JR, Rooney CM. Differential expression of viral and human interleukin-10 (IL-10) by primary B cell tumors and B cell lines. Virology 1994;200:724-32.
5. Vassilakopoulos TP, Nadali G, Angelopoulou MK, Siakantaris MP, Dimopoulou MN, Kontopidou FN, et al. Serum interleukin-10 levels are an independent prognostic factor for patients with Hodgkin's lymphoma. Haematologica 2001;86:274-81.
6. Visco C, Vassilakopoulos TP, Kliche KO, Nadali G, Viviani S, Bonfante V, et al. Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapy. Leuk Lymphoma 2004; 45:2085-92.
7. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997; 24:1-8.
8. Gibson AW, Edberg JC, Wu J, Westendorp RG, Huizinga TW, Kimberly RP. Novel single nucleotide polymorphisms in the distal IL-10 promoter affect IL-10 production ana enhance the risk of systemic lupus erythematosus. J Immunol 2001;166:3915-22.
9. Cunningham LM, Chapman C, Dunstan R, Bell MC, Joske DJ. Polymorphisms in the interleukin 10 gene promoter are associated with susceptibility to aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2003;44:251-5.
10. Rothman N, Skibola CF, Wang SS, Morgan G, Lan Q, Smith MT, et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol 2006;7: 27-38.
11. De Sanjose S, Nieters A, Goedert JJ, Domingo-Domenech E, Fernandez dS, Bosch R, et al. Role of hepatitis C virus infection in malignant lymphoma in Spain. Int J Cancer 2004; 111:81-5.
12. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835-49.
13. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219-34.
14. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842-54.
15. Rosenberg SA. Validity of the Ann Arbor staging classification for the non-Hodgkin's lymphomas. Cancer Treat Rep 1977;61:1023-7.
16. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
17. R Development Core Team. R: a language and environment for statistical computing. Vienna (Austria): Foundation for Statistical Computing; 2004.
18. Excoffier L, Slatkin M. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 1995; 12: 921-7.
19. Lech-Maranda E, Bienvenu J, Michallet AS, Houot R, Robak T, Coiffier B, et al. Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B-cell lymphoma. Eur Cytokine Netw 2006; 17:60-6.
20. Berglund M, Thunberg U, Roos G, Rosenquist R, Enblad G. The interleukin-10 gene promoter polymorphism (-1082) does not correlate with clinical outcome in diffuse large B-cell lymphoma. Blood 2005; 105:4894-5.
21. Purdue MP, Lan Q, Kricker A, Grulich AE, Vajdic CM, Turner J, et al. Polymorphisms in immune function genes and risk of non-Hodgkin lymphoma: findings from the New South Wales non-Hodgkin lymphoma study. Carcinogenesis 2007; 28:704-12.
22. Lin MT, Storer B, Martin PJ, Tseng LH, Gooley T, Chen PJ, et al. Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med 2003;349:2201-10.
23. Alonso R, Suarez A, Castro P, Lacave AJ, Gutierrez C. Influence of interleukin-10 genetic polymorphism on survival rates in melanoma patients with advanced disease. Melanoma Res 2005;15:53-60.
24. Karabon L, Wysoczanska B, Bogunia-Kubik K, Suchnicki K, Lange A. IL-6 and IL-10 promoter gene polymorphisms of patients and donors of allogeneic sibling hematopoietic stem cell transplants associate with the risk of acute graft-versus-host disease. Hum Immunol 2005;66:700-10.